SYNE1 and neoplasm: The data presented here verify the feasibility of using p700 as an alternative to monoclonal antibodies in directing CPG2 to tumour cells, its key advantages being small size (<2 kDa versus 150 kDa), lack of immunogenicity and multi-receptor binding.